These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25873248)

  • 21. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome.
    Häuser W; Urrútia G; Tort S; Uçeyler N; Walitt B
    Cochrane Database Syst Rev; 2013 Jan; (1):CD010292. PubMed ID: 23440848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Milnacipran for fibromyalgia.
    Dempsey J
    Issues Emerg Health Technol; 2008 Feb; (114):1-4. PubMed ID: 18354855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium.
    Bernstein CD; Albrecht KL; Marcus DA
    Expert Opin Pharmacother; 2013 May; 14(7):905-16. PubMed ID: 23506481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Milnacipran for treatment of fibromyalgia.
    Kyle JA; Dugan BD; Testerman KK
    Ann Pharmacother; 2010 Sep; 44(9):1422-9. PubMed ID: 20716692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Milnacipran for pain in fibromyalgia in adults.
    Cording M; Derry S; Phillips T; Moore RA; Wiffen PJ
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD008244. PubMed ID: 26482422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Milnacipran: in fibromyalgia.
    Chwieduk CM; McCormack PL
    Drugs; 2010; 70(1):99-108. PubMed ID: 20030428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of a randomized, placebo-controlled trial of milnacipran.
    Arnold LM; Palmer RH; Gendreau RM; Chen W
    Psychosomatics; 2012; 53(4):371-9. PubMed ID: 22677218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study.
    Goldenberg DL; Clauw DJ; Palmer RH; Mease P; Chen W; Gendreau RM
    Pain Med; 2010 Feb; 11(2):180-94. PubMed ID: 20002596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial.
    Clauw DJ; Mease PJ; Palmer RH; Trugman JM; Wang Y
    Arthritis Res Ther; 2013 Aug; 15(4):R88. PubMed ID: 23953493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program.
    Arnold LM; Bateman L; Palmer RH; Lin Y
    Pediatr Rheumatol Online J; 2015 Jun; 13():27. PubMed ID: 26112278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials.
    Mease PJ; Palmer RH; Wang Y
    J Clin Rheumatol; 2014 Jun; 20(4):195-202. PubMed ID: 24847745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study.
    Trugman JM; Palmer RH; Ma Y
    Curr Med Res Opin; 2014 Apr; 30(4):589-97. PubMed ID: 24188161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial.
    Lee YC; Massarotti E; Edwards RR; Lu B; Liu C; Lo Y; Wohlfahrt A; Kim ND; Clauw DJ; Solomon DH
    J Rheumatol; 2016 Jan; 43(1):38-45. PubMed ID: 26628607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization and consequences of pain variability in individuals with fibromyalgia.
    Harris RE; Williams DA; McLean SA; Sen A; Hufford M; Gendreau RM; Gracely RH; Clauw DJ
    Arthritis Rheum; 2005 Nov; 52(11):3670-4. PubMed ID: 16258905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ACS chemical neuroscience molecule spotlight on savella.
    Hopkins CR
    ACS Chem Neurosci; 2010 May; 1(5):345. PubMed ID: 22778830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current progress in the pharmacological therapy of fibromyalgia.
    Rao SG
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1479-93. PubMed ID: 19732029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Milnacipran: beyond a role of antidepressant.
    Pae CU; Marks DM; Shah M; Han C; Ham BJ; Patkar AA; Masand PS
    Clin Neuropharmacol; 2009; 32(6):355-63. PubMed ID: 19620845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pooled analysis of two randomized, double-blind, placebo-controlled trials of milnacipran monotherapy in the treatment of fibromyalgia.
    Geisser ME; Palmer RH; Gendreau RM; Wang Y; Clauw DJ
    Pain Pract; 2011; 11(2):120-31. PubMed ID: 20642487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacotherapy of fibromyalgia.
    Mease PJ; Dundon K; Sarzi-Puttini P
    Best Pract Res Clin Rheumatol; 2011 Apr; 25(2):285-97. PubMed ID: 22094202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Milnacipran hydrochloride: its efficacy, safety and tolerability profile in fibromyalgia syndrome.
    Owen RT
    Drugs Today (Barc); 2008 Sep; 44(9):653-60. PubMed ID: 19137120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.